Ann-Muriel Steff

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Respiratory Syncytial Virus

Top Venues

Journal of applied toxicology : JAT

Science advances

Nature communications

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

James A Williams, Marco Biancucci, Laura N Lessen, Sai Tian, Ankita Balsaraf, Lynn Chen, Chelsy C Chesterman, Giulietta Maruggi, Sarah Vandepaer, Ying Huang, Corey P Mallett, Ann-Muriel Steff, Matthew James Bottomley, Enrico Malito, Newton Wahome, Wayne D Harshbarger
Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity. Science advances 9 (23) (2023)
Rineke de Jong, Norbert Stockhofe-Zurwieden, Judith Bonsing, Kai-Fen Wang, Sarah Vandepaer, Badiaa Bouzya, Jean-François Toussaint, Ilse Dieussaert, Haifeng Song, Ann-Muriel Steff
ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves. Nature communications 13 (1) (2022)
Camille Planty, Guillaume Chevalier, Marie-Ève Duclos, Clémentine Chalmey, Catherine Thirion-Delalande, Cécile Sobry, Ann-Muriel Steff, Eric Destexhe
Nonclinical safety assessment of repeated administration and biodistribution of ChAd3-EBO-Z Ebola candidate vaccine. Journal of applied toxicology : JAT 40 (6) (2020)
Ann-Muriel Steff, Chanel Cadieux-Dion, Gaël de Lannoy, Maria Key Prato, Xavier Czeszak, Bruno André, Dominique C Ingels, Marc Louckx, Walthère Dewé, Marta Picciolato, Koen Maleux, Laurence Fissette, Ilse Dieussaert
Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants. Human vaccines & immunotherapeutics 16 (6) (2020)